Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.8%

2 terminated out of 52 trials

Success Rate

95.0%

+8.5% vs benchmark

Late-Stage Pipeline

23%

12 trials in Phase 3/4

Results Transparency

26%

10 of 38 completed with results

Key Signals

10 with results95% success

Data Visualizations

Phase Distribution

44Total
Not Applicable (21)
P 1 (2)
P 2 (9)
P 3 (8)
P 4 (4)

Trial Status

Completed38
Unknown5
Withdrawn3
Recruiting3
Terminated2
Active Not Recruiting1

Trial Success Rate

95.0%

Benchmark: 86.5%

Based on 38 completed trials

Clinical Trials (52)

Showing 20 of 20 trials
NCT07563621Recruiting

Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors

NCT05562518Phase 4Active Not RecruitingPrimary

GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.

NCT06900374Not ApplicableRecruiting

Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients

NCT07250490CompletedPrimary

Validation of the DIVA (Day to Day Impact of Vaginal Aging) Questionnaire for Portuguese Women

NCT04746456CompletedPrimary

Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM

NCT06846216Not ApplicableCompletedPrimary

Combination of BTL-785F and HPM-6000UF Devices for Women's Intimate Wellness

NCT05586711Phase 4CompletedPrimary

Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women

NCT05367973Phase 1CompletedPrimary

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

NCT05418426Phase 1CompletedPrimary

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

NCT04579991Not ApplicableRecruiting

Effects of Visnadin, Ethyl Ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women

NCT02460302Phase 2Withdrawn

Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy

NCT06144814Not ApplicableCompletedPrimary

A Comparison of Hyaluronic Acid and Estradiol Treatment in Vulvovaginal Atrophy.

NCT04487392Phase 2WithdrawnPrimary

Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women.

NCT03536585Not ApplicableCompletedPrimary

Multi-polar RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity

NCT04210583Not ApplicableCompletedPrimary

RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity

NCT03725410Not ApplicableCompletedPrimary

Multi-polar RF and PEMF for Treatment of Symptoms Associated With Vulvovaginal Atrophy

NCT04219722Not ApplicableCompletedPrimary

Efficacy and Safety of Hyaluronic Acid Injection on Symptoms of Vulvovaginal Atrophy in Postmenopausal Women

NCT04766957Not ApplicableCompletedPrimary

Pilot Clinical Trial of IDRACARE® in Moderate to Severe Symptoms of Vulvovaginal Atrophy

NCT04887701Not ApplicableCompletedPrimary

Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women

NCT03666819Phase 2Withdrawn

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Scroll to load more

Research Network

Activity Timeline